Wegovy 1.7mg FlexTouch is a prescription medicine that belongs to a class called GLP-1 receptor agonists. It works in a way similar to a natural hormone in the body that helps manage hunger, digestion, and blood sugar. It works best when combined with healthy eating habits and regular physical activity.

Wegovy 1.7mg FlexTouch is used along with a reduced-calorie diet and increased physical activity to help lower the risk of major heart-related events, such as heart attack, stroke, or cardiovascular death, in adults who have established heart disease and also have obesity or overweight. It is also prescribed for long-term weight management in adults and adolescents aged 12 years and older with obesity, and in adults with overweight who have a weight-related health condition. In addition, Wegovy 1.7mg FlexTouch is used to treat noncirrhotic nonalcoholic steatohepatitis (NASH) in adults who have moderate to advanced liver scarring.

Wegovy 1.7mg FlexTouch is administered as a once-weekly injection. It is generally injected under the skin in your abdomen, thigh, or upper arm. Get the injection on the same day each week, at a similar time, to maintain consistent levels in your body. Along with the treatment, maintain a healthy diet and exercise regularly for maximum benefits.

The most common side effects of Wegovy 1.7mg FlexTouch include nausea, vomiting, diarrhea, stomach pain, constipation, and headache. These symptoms often occur during the initial stage; however, they usually improve over time as your body adjusts to the medication. Eating smaller meals or avoiding heavy, fried foods may help ease symptoms like nausea or an upset stomach. If you experience severe or persistent side effects, consult your doctor for advice.

Before starting Wegovy 1.7mg FlexTouch, inform your doctor about any medical conditions you have, particularly a history of pancreatitis, eye problems caused by diabetes (diabetic retinopathy), thyroid cancer, or severe gastrointestinal problems. This medicine is not recommended for individuals with a personal or family history of medullary thyroid carcinoma or those with multiple endocrine neoplasia syndrome type 2 (MEN 2).

Additionally, discuss with your doctor if you are on medications for type 2 diabetes, such as insulin or sulfonylureas; combining Wegovy 1.7mg FlexTouch with these medications can increase the risk of low blood sugar levels (hypoglycemia). Your doctor may need to adjust your medicine dosage to ensure safe use.